Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I onset of action trial in patients with hyperkalaemia.

Next Previous
Trial Profile

Phase I onset of action trial in patients with hyperkalaemia.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Relypsa

    • Most Recent Events

    • 21 Jul 2017 According to a Relypsa media release, the European Commission (EC) approved the Marketing Authorization Application (MAA) for Veltassa (patiromer) for the treatment of hyperkalemia.
    • 19 May 2017 According to a Vifor media release, based on the results from this trial, Phase 2 AMETHYST-DN trial, and Phase III OPAL-HK trial, The Committee For Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for patiromer for the treatment of hyperkalemia.
    • 25 Apr 2016 According to Relypsa media release, patiromer was approved by the US Food and Drug Administration (FDA) for the treatment of hyperkalemia in the US in October 2015 under the name Veltassa, becoming the first new medicine in more than 50 years for people with elevated serum potassium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top